Melan-A analog peptide

BIOLOGICAL2 trials

Sponsors

Centre Hospitalier Universitaire Vaudois, University of Lausanne Hospitals

Conditions

Melanoma

Phase 1

Immunotherapy of Melanoma Patients

CompletedNCT00112216

Centre Hospitalier Universitaire VaudoisMelanoma

Start: 1999-05-31End: 2007-06-30Updated: 2013-04-24

Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients

SuspendedNCT00160992

University of Lausanne HospitalsMelanoma

Start: 2004-07-31End: 2005-08-31Target: 6Updated: 2005-09-12